Low levels of CD38 expression on myeloma cells during daratumumab treatment are hypothesized to be due to trogocytosis of the CD38‐daratumumab complex by monocytes and granulocytes, whereby a cell extracts and ingests “bites” of material from another cell.138, 139, 140. The gene discussed is CD38; the disease is plasma cell myeloma.